Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

B of A Securities Downgrades PTC Therapeutics to Underperform, Announces $38 Price Target

B of A Securities analyst Tazeen Ahmad downgrades PTC Therapeutics (NASDAQ:PTCT) from Neutral to Underperform and announces $38 price target.
byBenzinga Newsdesk
October 18, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

B of A Securities analyst Tazeen Ahmad downgrades PTC Therapeutics (NASDAQ:PTCT) from Neutral to Underperform and announces $38 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0